Ophthalmological composition having a plurality of comonomer groups, and ophthalmological lens

Abstract

The invention relates to an ophthalmological composition for producing an ophthalmological lens (10), comprising comonomer groups A) to C), at least one comonomer group which is D), E) or a mixture thereof, and at least one crosslinker F). Here: A) denotes at least one (meth)acrylate having at least one aromatic group; B) denotes at least one (meth)acrylate having an aliphatic or non-aromatic cyclic or non-aromatic heterocyclic group; C) denotes at least one (meth)acrylate having at least one hydroxyl group; D) denotes at least one (meth)acrylamide having an aromatic group and having an aliphatic or non-aromatic cyclic or non-aromatic heterocyclic group; and E) denotes a mixture of at least one (meth)acrylamide having two aromatic groups and at least one (meth)acrylamide having two aliphatic and / or non-aromatic cyclic and / or non-aromatic heterocyclic groups. Each of the comonomer groups comprises respectively determined components, based on the total weight of the ophthalmological composition. The invention also relates to an ophthalmological lens (10), which is produced at least in part from such an ophthalmological composition.

Description

[0001] Ophthalmic composition with multiple comonomer groups and ophthalmic lens

[0002] Technical area

[0003] The invention relates to an ophthalmic composition comprising a plurality of comonomer groups and to an ophthalmic lens, in particular a soft intraocular lens, which is at least partially made from such an ophthalmic composition.

[0004] State of the art

[0005] In recent decades, a wide range of different biomaterials have been developed for the manufacture of ophthalmic composites and lenses, particularly intraocular lenses (IOLs). The various classes of materials include hydrophilic polymers, hydrophobic polymers, and silicone. Each class has its own advantages and disadvantages. While silicone IOLs exhibit very good resistance to posterior capsule opacity (PCO), their post-injection unfolding behavior can be uncontrollable. Hydrophilic lenses generally exhibit very good biocompatibility but also higher PCO and calcification rates. Hydrophobic IOLs have experienced the greatest growth in recent years.They typically offer a relatively high refractive index in the range of n = 1.44–1.55, but carry the risk of so-called glistening, which is characterized by water-containing microvacuoles forming within the polymer matrix and which can disrupt the patient's visual perception, particularly in multifocal lenses. Vacuoles with diameters of less than 200 nm, located up to 120 pm below the surface of the IOL, are also referred to as subsurface nanoglistenings (SSNG).

[0006] US 2002 / 0049290 A1 discloses optically transparent hydrogels with a high refractive index and intraocular lenses made therefrom. The preferred hydrogels have a refractive index of 1.45 or more and a water content of approximately 5 to 30 weight percent. WO 99 / 58507 A1 discloses hydrophilic, UV-absorbing, polymerizing monomers. These monomers are copolymerizable and yield biocompatible hydrogels that can absorb at least 90% of the UV light incident on the hydrogels. Such hydrogels are optically transparent, have high refractive indices, and possess long-term stability.

[0007] US 2013 / 0231 740 A1 discloses relatively soft, optically transparent, foldable materials with a high refractive index that are particularly suitable for use in the manufacture of intraocular lenses, contact lenses and other ocular implants.

[0008] Tailoring a material for such a specific application as an ophthalmic lens requires complex multi-parameter optimization. In addition to ensuring biocompatibility, the optical, physical, and mechanical properties must also be optimized. For example, a material with excellent biocompatibility but low flexibility is not ideal, as this would result in larger incisions for IOL implantation. This is particularly important given the increasing trend toward smaller incisions (micro-incision cataract surgery, MICS with < 2 mm incisions). The selection of the base material is particularly crucial here. Hydrophobic polymers inherently offer good basic properties for the development of a MICS-compatible material, namely high tensile strength combined with a high refractive index.However, glistening resistance and material flexibility must be significantly increased. A new class of materials, the so-called "new hydrophobic acrylates," has been the result of recent research in the field of IOL materials. An overview of the currently common material classes is provided in Table 1 below.

[0009] Table 1: Physical properties of common IOL materials "Hyg." refers to the mass percentage of water in the lens at equilibrium at 35°C. "Contact angle" is the angle between the leading edge of a water droplet and the material surface. "Tensile strength" is the greatest stress the material class can withstand while being pulled without breaking. "Refractive index n" refers to the refractive index at 20°C. "Tg" refers to the glass transition temperature.

[0010] Hydrophilic materials typically have a low refractive index, which decreases even further when fully hydrated. Therefore, the lens curvature and thickness must automatically be more pronounced for high diopters than for materials with a higher refractive index. This requires the implantation of a large lens cross-section through a small injection tip, which increases the risk of damage to the cartridge tip of the implantation tool or the lens itself. Greater material flexibility can be achieved with these materials through high water absorption of 5 to 30 percent. However, this not only significantly reduces the refractive index but also requires the lenses to be stored in aqueous or at least humidity-controlled packaging. Otherwise, dimensional stability and optical quality after lens implantation cannot be guaranteed.

[0011] The main idea behind the "new hydrophobic acrylates" is to add the hydrophilic monomer HEMA (2-hydroxyethyl methacrylate) to otherwise hydrophobic comonomers, due to its ability to disperse water throughout the material. Common ophthalmic compositions contain approximately 30% HEMA to be glisten-free and approximately 4% water by weight in equilibrium. Due to the latter proportion, corresponding IOLs must be stored in a 0.9% saline solution and are therefore not suitable for dry preloaded IOL implantation systems.

[0012] With some "new hydrophobic acrylates," the risk of glistening has supposedly been reduced, albeit at the cost of a relatively low refractive index (nd<1.5). This means, as already mentioned, that the cross-section of the lens and thus the required cut size must be significantly increased depending on the diopter number. Furthermore, these materials exhibit a relatively slow lens unfolding rate under simulated surgical conditions (26°C water bath) and are not suitable for steam sterilization, which severely limits the options for sterilization procedures, which are essential for ophthalmic implants.

[0013] Thus, recent developments in the field of IOL biomaterials point to an interesting direction for further development, but improvements are still needed towards implants that offer a faster and less invasive surgical workflow combined with higher patient satisfaction.

[0014] Description of the invention

[0015] The object of the present invention is therefore to create an ophthalmic composition that enables the production of flexible, biocompatible ophthalmic lenses with a high refractive index while minimizing the risk of glistening. An ophthalmic lens produced from the composition can be stored in a dry environment and sterilized by steam sterilization. A further object of the invention is to provide a corresponding ophthalmic lens.

[0016] These objects are achieved according to the invention by an ophthalmic composition having the features of claim 1 and an ophthalmic lens according to claim 6. Advantageous embodiments with expedient further developments of the invention are specified in the respective subclaims, wherein advantageous embodiments of the ophthalmic composition are to be regarded as advantageous embodiments of the ophthalmic lens and vice versa.

[0017] A first aspect of the invention relates to an ophthalmic composition for producing an ophthalmic lens, comprising comonomer groups A) to C), at least one comonomer group which is D), E) or a mixture thereof, and at least one crosslinker F). A) denotes at least one (meth)acrylate having at least one aromatic group, B) at least one (meth)acrylate having an aliphatic or non-aromatic cyclic or non-aromatic heterocyclic group, C) at least one (meth)acrylate having at least one hydroxyl group, D) at least one (meth)acrylamide having an aromatic group and having an aliphatic or non-aromatic cyclic or non-aromatic heterocyclic group, and E) a mixture of at least one (meth)acrylamide having two aromatic groups and at least one (meth)acrylamide having two aliphatic and / or non-aromatic cyclic and / or non-aromatic heterocyclic groups.In other words, the invention provides that the ophthalmic composition contains monomers from at least four or five different molecular classes A), B), C), D) or A), B), C), E) or A), B), C), D), E) as well as at least one crosslinker F) or, in the simplest embodiment, consists of the aforementioned molecular classes and contains no further molecular classes. The composition according to the invention is preferably silicon-free or siloxane-free and preferably free from fluorinated compounds. In the synthesis of a polymer from the ophthalmic composition according to the invention, the molecular classes A) to E) function as comonomers which can be crosslinked with the aid of the crosslinker F). The composition according to the invention can therefore also be referred to as a prepolymer.In the context of the present disclosures, the term "(meth)acrylate" always refers to acrylates, methacrylates, and any mixtures thereof, unless specific individual compounds are expressly discussed. For example, the term "2-phenylethyl (meth)acrylate" encompasses the compounds 2-phenylethyl acrylate, 2-phenylethyl methacrylate, and any mixtures of the two compounds. The same applies to the term "(meth)acrylamide," which always also encompasses acrylamide, methacrylamide, or a mixture thereof, unless specific individual compounds are expressly discussed. In general, "a" / "an" should be read as an indefinite article in the context of this disclosure, i.e., unless expressly stated otherwise, always also as "at least one." Conversely, "a" / "an" can also be understood as "only one."

[0018] The ophthalmic composition according to the invention is particularly suitable for the production of soft, MICS-compatible intraocular lenses, but can also be used in principle for the production of other ophthalmic lenses, implants, keratoprostheses, inlays, and the like. At the same time, the composition according to the invention enables the production of ophthalmic lenses that offer high patient satisfaction due to their very low tendency to glisten. The surgical workflow during implantation can also be improved by a fast, controllable unfolding speed of the lenses produced from the composition. The ophthalmic composition according to the invention also allows the production of ophthalmic lenses that can be used in fully preloaded injector systems with dry and wet storage.This reduces manufacturing complexity and facilitates storage while maintaining full design freedom. Finally, the ophthalmic composition according to the invention, or a lens made from it, can be sterilized by steam sterilization. This not only opens up a wider range of production processes but also allows for the use of a more sustainable and cost-effective method compared to the established ethylene oxide (EtO) sterilization of common hydrophobic IOLs.

[0019] The present invention is based on the finding that in order to design a polymeric biomaterial that combines as many of the above-mentioned requirements as possible, an ophthalmic composition is needed that contains at least four different classes of monomers or comonomers, each with different properties.

[0020] The first group A) can also be referred to as "aromatic monomers," which contain at least one aromatic group or an aryl ring to increase the refractive index of the resulting polymer. The term "aryl ring" encompasses both individual rings, for example, phenyl, and fused and isolated aromatic ring systems, for example, naphthyl or biphenyl rings. The aryl ring(s) can each bear one or more substituents. The aryl ring is preferably selected from C-C11 aryl groups.

[0021] The second group B) comprises monomers with an aliphatic group, which can be used to increase the flexibility of the material. Alternatively or in addition to an open-chain aliphatic group, one or more non-aromatic cyclic groups, for example a cyclohexyl group, and / or one or more non-aromatic heterocyclic groups, for example a piperidinyl group, can also be provided. The aliphatic group is preferably selected from C 1-12 alkyl groups, which are preferably unbranched or, where possible, branched. The heterocyclic group preferably has at least one atom from the group N, S, and / or O and is suitable for the formation of hydrogen bonds. The aliphatic group(s) are preferably linear, but in principle can also be branched.Furthermore, any aliphatic, non-aromatic cyclic or non-aromatic heterocyclic group may also comprise one or more carbon double and / or triple bonds.

[0022] The third group C) contains one or more monomers that have at least one hydroxyl group. These are preferably one or more terminal or sterically unhindered hydroxyl groups that are capable of forming hydrogen bonds in the polymer. The third group C) is added primarily to increase the water absorption of the polymer composition.

[0023] The fourth group D) contains "hybrid" (meth)acrylamide comonomers, which lead to a surprising improvement in the resulting biomaterial properties. The molecular class D), defined here as "hybrid" (meth)acrylamide comonomers, comprises a vinyl functionality for polymerization as well as a tertiary amide. The advantage of using an acrylamide over an acrylate is that two terminal substituents can be attached per monomer unit. In the case of "hybrid" acrylamides, both substituents or functional groups in group D) are different. A comonomer of group D) thus has the general formula (I) in which R 1 =H / CHs, R 2 =Aryl-containing residue and R 3 =alkyl radical, where R 2 and / or R 3 are preferably unsubstituted. The two substituents R 2 or R 3are selected so that they preferably have the same or as similar as possible chemical structures to those of the aromatic monomer A) or the aliphatic monomer B) used in the ophthalmic composition in question. Accordingly, the same considerations and limitations generally apply to the substituents of the comonomer of group D) as to the substituents of the comonomers of groups A) and B). These structural similarities result in advantageous intermolecular interactions between the different comonomer groups A), B) and D) in the final polymer, with the acrylamide D) acting as a kind of mediator between groups A) and B). The aryl group of acrylamide D) also advantageously leads to an increase in the refractive index and forms TT-TT interactions with the molecules of the aromatic monomer A), which leads to greater structural strength of the polymer.The alkyl group of the acrylamide D) can increase the flexibility of the material or, in the case of branched or cyclic / heterocyclic substituents, also provide greater lightfastness and tear resistance. In certain embodiments, R. 3 in formula (I), however, may also be substituted, in particular, with one or more hydroxy groups. This makes it possible for comonomer D) to be structurally similar to comonomer C), so that advantageous intermolecular interactions can be formed between groups A), C), and D).

[0024] Alternatively or in addition to group D), group E) can also be used. The two groups D) and E) are therefore used synonymously below. Group E) comprises a mixture of at least two different (meth)acrylamides, wherein a first (meth)acrylamide has two aromatic groups and a second (meth)acrylamide has two aliphatic and / or non-aromatic cyclic and / or non-aromatic heterocyclic groups. In other words, group E) comprises two molecule classes of the general formulas IIa, IIb (lla, llb), where in the formula Ila R 1 =H / CHs and R 2 and R 3 =Aryl-containing residue and in the formula llb R 1 =H / CHs and R 2 and R 3 =alkyl radical, where R 2 and R 3are independently unsubstituted and / or substituted in particular with one or more hydroxy groups in order to be able to interact with comonomers of group C). The two substituents R 2 ' R 3of a (meth)acrylamide can therefore be the same or different. Otherwise, the same considerations and limitations apply to the substituents of group E) as to the substituents of groups A), B), and C). In contrast to group D), group E) is not an intramolecular "hybrid" (meth)acrylamide, but rather a "hybrid" mixture of at least two different (meth)acrylamides, whereby the mixture E) can also act as a kind of mediator between groups A) and B) or C) in the polymer. The individual compounds of group E) can sometimes be synthesized more easily and cost-effectively than the hybrid compounds of group D), especially if the individual (meth)acrylamides each have two identical substituents R 2 ' R 3 carry.

[0025] Finally, to produce an elastomeric, biocompatible polymer suitable for use as a soft IOL and preferably not a thermoplastic, at least one crosslinker F) is provided, which is designed to create covalent bonds between polymer chains that guarantee reliable unfolding and establish a balance between material strength and flexibility. Two or more different crosslinkers can also be provided, in particular to adjust the mechanical properties of the polymer.

[0026] Since polymer chains regularly contain regions that are more tightly folded and others that are more loosely folded, pockets of lower density can lead to a local accumulation of water, especially when the environmental conditions change rapidly (for example, during a temperature shock). The invention is therefore also based on the finding that this risk can be significantly reduced by using flexible substituents that can orient themselves freely. This applies in particular to unsubstituted or substituted alkyl groups, such as those found in the comonomer groups B),

[0027] C), D) and E) are or may be provided for.

[0028] On the other hand, it was also recognized that it is very important to use hydrophilic or hygroscopic comonomers that are distributed as homogeneously as possible in the polymer matrix. These comonomers (group C) not only stabilize water locally through the formation of hydrogen bonds, but also form non-covalent bonds with the functional groups of the amide (group

[0029] D) / E)), which leads to a higher structural strength of the polymer. According to the invention, it is provided that, based on the total weight of the ophthalmological composition, a proportion of the comonomer group A) is between 30 wt.% and 60 wt.%, that is to say, for example, 30 wt.%, 31 wt.%, 32 wt.%, 33 wt.%, 34 wt.%, 35 wt.%, 36 wt.%, 37 wt.%, 38 wt.%, 39 wt.%, 40 wt.%, 41 wt.%, 42 wt.%, 43 wt.%, 44 wt.%, 45 wt.%, 46 wt.%, 47 wt.%, 48 wt.%, 49 wt.%, 50 wt.%, 51 wt.%, 52 wt.%, 53 wt.%, 54 wt.%, 55 wt.%, 56 wt.%, 57 wt.%, 58 wt.%, 59 wt.% or 60 wt.%. The proportion of comonomer group B) is between 10 wt.% and 45 wt.%, i.e., for example, 10 wt.%, 11 wt.%, 12 wt.%, 13 wt.%, 14 wt.%, 15 wt.%, 16 wt.%, 17 wt.%, 18 wt.%, 19 wt.%, 20 wt.%, 21 wt.%, 22 wt.%, 23 wt.%, 24 wt.%, 25 wt.%, 26 wt.%, 27 wt.%, 28 wt.%, 29

[0030] wt%, 30 wt%, 31 wt%, 32 wt%, 33 wt%, 34 wt%, 35 wt%, 36

[0031] wt%, 37 wt%, 38 wt%, 39 wt%, 40 wt%, 41 wt%, 42 wt%, 43

[0032] % by weight, 44 % by weight or 45 % by weight. The proportion of the comonomer group C) is between

[0033] 5 wt% and 30 wt%, for example 5 wt%, 6 wt%, 7 wt%, 8

[0034] wt%, 9 wt%, 10 wt%, 11 wt%, 12 wt%, 13 wt%, 14 wt%, 15

[0035] wt%, 16 wt%, 17 wt%, 18 wt%, 19 wt%, 20 wt%, 21 wt%, 22

[0036] wt%, 23 wt%, 24 wt%, 25 wt%, 26 wt%, 27 wt%, 28 wt%, 29

[0037] % by weight or 30 % by weight. The proportion of the sum of the comonomer groups D) and E) is between 1 % by weight and 14 % by weight, for example 1 % by weight, 2 % by weight, 3 % by weight, 4 % by weight, 5 % by weight, 6 % by weight, 7 % by weight, 8 % by weight, 9 % by weight, 10 % by weight, 11 % by weight, 12 % by weight, 13 % by weight, or 14 % by weight. The proportion of the cross-linker F) is a maximum of 5 wt.%, i.e. for example 0.05 wt.%, 0.1 wt.%, 0.2 wt.%, 0.3 wt.%, 0.4 wt.%, 0.5 wt.%, 0.6 wt.%, 0.7 wt.%, 0.8 wt.%, 0.9 wt.%, 1.0 wt.%, 1.1 wt.%, 1.2 wt.%, 1.3 wt.%, 1.4 wt.%, 1.5 wt.%,

[0038] 1.6 wt%, 1.7 wt%, 1.8 wt%, 1.9 wt%, 2.0 wt%, 2.1 wt%, 2.2 wt%, 2.3 wt%, 2.4 wt%, 2.5 wt%, 2.6 wt%, 2.7 wt%, 2.8 wt%, 2.9 wt%, 3.0 wt%, 3.1 wt%, 3.2 wt%, 3.3 wt%, 3.4 wt%, 3.5 wt%,

[0039] 3.6 wt%, 3.7 wt%, 3.8 wt%, 3.9 wt%, 4.0 wt%, 4.1 wt%, 4.2 wt%, 4.3 wt%, 4.4 wt%, 4.5 wt%, 4.6 wt%, 4.7 wt%, 4.8 wt%, 4.9 wt% or 5.0 wt%. The proportion of the crosslinker F) is preferably between 0.5 wt% and 5 wt%. The (meth)acrylamide comonomers D) / E) are preferably used as a type of "additive" in the ophthalmic compositions. This means that the sum of the (meth)acrylamides D) / E) in wt% is preferably the smallest compared to the remaining comonomer types A) to C) of the composition. It is understood that the proportions of all components of the ophthalmic composition always and exclusively add up to 100% by weight. Generally, percentages within the scope of this disclosure are to be understood as percentages by mass, unless otherwise stated.

[0040] In an advantageous embodiment of the invention, the comonomer group A) comprises or is 2-phenylethyl acrylate, 2-phenylethyl methacrylate, ethylene glycol phenyl ether acrylate, ethylene glycol phenyl ether methacrylate, or a mixture thereof. Alternatively or additionally, the comonomer group B) comprises or is butyl acrylate, butyl methacrylate, isobutyl acrylate, isobutyl methacrylate, 2-ethylhexyl acrylate, 2-ethylhexyl methacrylate, or a mixture thereof. Alternatively or additionally, the comonomer group C) comprises or is 2-hydroxyethyl acrylate, 2-hydroxyethyl methacrylate, 4-hydroxybutyl acrylate, 4-hydroxybutyl methacrylate, or a mixture thereof.Alternatively or additionally, the comonomer group D) includes or is N-benzyl-N-isopropylacrylamide, N-benzyl-N-isopropylmethacrylamide, N-benzyl-N-butylacrylamide, N-benzyl-N-butylmethacrylamide, N-benzyl-N-isobutylacrylamide, N-benzyl-N-isobutylmethacrylamide, N-benzyl-N-isopentylacrylamide, N-benzyl-N- isopentylmethacrylamide, N-benzyl-N-pentylacrylamide, N-benzyl-N-pentylmethacrylamide, N-benzyl-N-methylacrylamide, N-benzyl-N-methylmethacrylamide or a mixture thereof. Alternatively or additionally, the comonomer group E) comprises or is N,N-dibenzyl(meth)acrylamide and N,N-diisopropyl(meth)acrylamide, N,N-dibenzyl(meth)acrylamide and N,N-dibutyl(meth)acrylamide, N,N-dibenzyl(meth)acrylamide and N,N-isobutyl(meth)acrylamide, N,N-dibenzyl(meth)acrylamide, N,N-diisopentyl(meth)acrylamide and N,N-dipentyl(meth)acrylamide, N,N-dibenzyl(meth)acrylamide and N,N-dimethyl(meth)acrylamide or a mixture thereof.Alternatively or additionally, F) comprises or is a crosslinker having at least two acrylate groups, at least two methacrylate groups, or at least one acrylate and at least one methacrylate group, wherein the crosslinker comprises or is in particular 1,4-butanediol diacrylate and / or ethylene glycol dimethacrylate. Such an ophthalmic composition is particularly suitable for the production of clear ophthalmic biomaterial having an advantageous refractive index n o,35°C in the hydrated state of about 1.50 or more, a Shore A hardness of less than 80 (t=3 s) or a Shore A hardness of less than 50 (t=10 min), a glass transition temperature between 0°C and 15°C, a water absorption capacity at 35°C between 0.5% by weight and 3.5% by weight, and an Abbe number of at least 30.

[0041] With regard to the Shore A hardness values, it should be noted that these can be determined within the scope of the present disclosure at different indentation times t. The indentation times t are specified in each case within the scope of the present disclosure. Normally, the measurement of an elastomer (for example rubber) is carried out after 3 seconds, as specified in DIN ISO 7619-1. The DIN-compliant Shore A limit value for the materials according to the invention is preferably at most 80 or less (t=3 s), more preferably at most 65 or less (t=3 s). Alternatively or additionally, the Shore A value is at most 50 or less for an indentation time t=10 min.

[0042] Further advantages arise from the fact that the ophthalmic composition contains at least one further component G), H), I) or a mixture thereof, where G) denotes at least one preferably covalently bondable UV absorber, H) at least one preferably covalently bondable dye for modifying the light absorption properties, and I) a polymerization initiator. With the aid of component G), UV absorption properties can be provided, preferably at least in the wavelength range between approximately 300 nm and approximately 400 nm. With the aid of component H), which can also be referred to as a yellow dye, the ophthalmic composition can be easily adapted to provide a yellow biomaterial for the production of lenses, which, for example, has its absorption maximum in the wavelength range between approximately 400 nm and approximately 500 nm.The amount of yellow dye used in the composition can be selected, if necessary, within a relatively wide concentration range in order to achieve a desired percentage transmission per wavelength in the range between approximately 400 nm and approximately 500 nm. Likewise, one or more of the components G) and / or H), which are preferably covalently bonded in the reacted polymer to prevent outward diffusion, can achieve a desired absorption profile of the biomaterial or of a lens made therefrom in the wavelength range suitable for the application.

[0043] The wavelength range visible to humans can be achieved. A polymerization initiator can be used to adjust the type and rate of the polymerization reaction of the ophthalmic composition.

[0044] Further advantages with regard to various properties of the ophthalmic composition and a biomaterial formed therefrom result from the fact that, based on the total weight of the ophthalmic composition, a proportion of component G) is a maximum of 2 wt.%, i.e. for example 0.1 wt.%, 0.2 wt.%, 0.3 wt.%, 0.4 wt.%, 0.5 wt.%, 0.6 wt.%, 0.7 wt.%, 0.8 wt.%, 0.9 wt.%, 1.0 wt.%, 1.1 wt.%, 1.2 wt.%, 1.3 wt.%, 1.4 wt.%, 1.5 wt.%, 1.6 wt.%, 1.7 wt.%, 1.8 wt.%, 1.9 wt.% or 2.0 wt.%, in particular a maximum of 1 wt.%. and / or component H) a maximum of 5 wt.%, i.e. for example 0.1 wt.%, 0.2 wt.%, 0.3 wt.%, 0.4 wt.%, 0.5 wt.%, 0.6 wt.%, 0.7 wt.%, 0.8 wt.%, 0.9 wt.%, 1 ,0 wt.%, 1.1 wt.%, 1 ,2 wt.%, 1 ,3 wt.%, 1 ,4 wt.%, 1 ,5 wt.%, 1 ,6 wt.%, 1 ,7 wt.%, 1 ,8 wt.%, 1 ,9 wt.%, 2.0 wt.%, 2.1 wt.%, 2.2 wt.%, 2.3 wt.%, 2.4 wt.%, 2.5 wt%, 2.6 wt%, 2.7 wt%,

[0045] 2.8 wt%, 2.9 wt%, 3.0 wt%, 3.1 wt%, 3.2 wt%, 3.3 wt%, 3.4 wt%, 3.5 wt%, 3.6 wt%, 3.7 wt%, 3.8 wt%, 3.9 wt%, 4.0 wt%, 4.1 wt%, 4.2 wt%, 4.3 wt%, 4.4 wt%, 4.5 wt%, 4.6 wt%, 4.7 wt%,

[0046] 4.8 wt.%, 4.9 wt.% or 5.0 wt.%, and / or component I) a maximum of 3 wt.%, i.e. for example 0.1 wt.%, 0.2 wt.%, 0.3 wt.%, 0.4 wt.%, 0.5 wt.%, 0.6 wt.%, 0.7 wt.%, 0.8 wt.%, 0.9 wt.%, 1.0 wt.%, 1.1 wt.%, 1.2 wt.%, 1.3 wt.%, 1.4 wt.%, 1.5 wt.%, 1.6 wt.%, 1.7 wt.%, 1.8 wt.%, 1.9 wt.%, 2.0 wt.%, 2.1 wt.%, 2.2 wt%, 2.3 wt%, 2.4 wt%, 2.5 wt%, 2.6 wt%, 2.7 wt%, 2.8 wt%, 2.9 wt% or 3.0 wt%.

[0047] It has further proven advantageous if the UV absorber G) is 2-(5-chloro-2H-benzotriazol-2-yl)-6-(1,1-dimethylethyl)-4-ethenylphenol) (IIVAM). Alternatively or additionally, it has proven advantageous if the dye H) is the yellow dye 4-(3-vinylphenylazo)diphenylamine (3VPADPA or VPAD). Since the yellow dye absorbs in the range between 400 nm and 500 nm, it is also referred to as a “blue light absorber”. These compounds, individually or in any combination, allow the production of a biomaterial with an absorption profile that is particularly advantageous for ophthalmic lenses in the wavelength range between approximately 300 nm and 400 nm (G)) or between approximately 400 nm and approximately 500 nm (H)). In other words, the absorption profile in the specified wavelength range can be adjusted as desired using a combination of UV and blue light absorbers (G), H). High-energy blue light is thus reduced.If no blue light absorber (H)) is added, but only the UV absorber (G)) is used, the absorption cut-off is preferably set at about 400 nm and the biomaterial according to the invention remains colorless with maximum UV protection.

[0048] A second aspect of the present invention relates to an ophthalmic lens which is at least partially produced from an ophthalmic composition according to the first aspect of the invention. The ophthalmic lens is, in particular, a soft intraocular lens. In certain embodiments, the lens may have an optical part and a haptic part. The lens may further consist of two or more different biomaterials, of which at least one biomaterial is according to the invention. Preferably, the entire lens is produced from one or more compositions or biomaterials according to the invention. Therefore, in some embodiments, the lens may have two or more regions with different optical, physical, and / or mechanical properties. However, it may also be provided that the ophthalmic lens is designed as a contact lens.By using the ophthalmic composition according to the first aspect of the invention to realize the ophthalmic lens according to the second aspect of the invention, the lens according to the invention is flexible, biocompatible, and has a high refractive index under physiological conditions with a particularly low risk of glistening. Furthermore, the ophthalmic lens can be stored dry and sterilized by steam sterilization. Further resulting features and their advantages can be found in the descriptions of the first aspect of the invention, with advantageous embodiments of the first aspect of the invention being regarded as advantageous embodiments of the second aspect of the invention, and vice versa.

[0049] In an advantageous embodiment of the invention, the ophthalmic lens in a non-hydrated state has a refractive index nD,20°c > 1.51 and / or in a hydrated state a refractive index n0,35°c > 1.50 and / or a Shore A hardness of less than 80 (t=3 s), in particular of at most 65 (t=3 s) or a Shore A hardness of less than 50 (t=10 min) and / or a glass transition temperature between 0 °C and 15 °C, in particular between 4 °C and 9 °C and / or a water absorption capacity at 35 °C between 0.5 wt.% and 3.5 wt.%, in particular between 1.5 wt.% and 2.5 wt.% and / or an Abbe number of at least 30, preferably at least 40. The ophthalmic lens according to the invention hereby combines one or more particularly advantageous properties. Preferably, the ophthalmic lens fulfills all of the above-mentioned properties.

[0050] In a further advantageous embodiment of the invention, it is provided that the ophthalmic lens in an in vitro glistening test by accelerated aging, in which the lens is first placed in a saline solution at 45 °C ± 1 °C for 24 h and then at 37 °C ± 1 °C for 2.5 h, has a microvacuole density of at most 10 MVs / mm 2 , preferably not more than 1 MVs / mm 2In other words, the ophthalmic lens advantageously has a particularly low microvacuole density, wherein the microvacuole density is determined using the aforementioned test method. The saline solution is preferably a physiological saline solution (NaCl concentration 9 g / l, osmolarity 308 mOsm / l). This completely or at least essentially completely prevents problems otherwise caused by glistening, for example, glare symptoms when driving at night with oncoming light or on a sunny day. The lens is particularly preferably glistening-free and, in particular, microvacuole-free, which is easily achievable due to the use of the ophthalmic composition according to the invention.

[0051] In a further advantageous embodiment of the invention, the ophthalmic lens is steam sterilized. This allows the lens according to the invention to be sterilized cost-effectively using established steam sterilization, advantageously eliminating the need for chemical sterilization processes. Alternatively or additionally, the ophthalmic lens is plasma-treated. This advantageously reduces surface stickiness. The plasma treatment can be carried out, for example, in an oven with an RF plasma generator (e.g., 13.56 MHz) and in a mixed atmosphere of oxygen and argon (e.g., 23 sccm O2, 127 sccm Ar, 400 mtorr) at 100 W to 800 W, preferably at approximately 400 W for 1 to 10 minutes, in particular for approximately 5 minutes per IOL side. The power and duration can be varied as needed to achieve the desired surface properties.In the plasma furnace, the oxygen can be converted into ozone, thereby intensifying the treatment. Alternatively or additionally, the ophthalmic lens is stored in a preferably non-hydrated state in a storage cartridge and / or in an implantation tool for implanting the lens into an eye. Alternatively or additionally, the lens according to the invention can advantageously be used for dry and, if necessary, fully pre-loaded injection systems and does not need to be packaged or stored in liquid. This simplifies packaging and significantly extends shelf life and handling.

[0052] A polymeric biomaterial produced by polymerization from the ophthalmic composition according to the first aspect of the invention represents a further independent aspect of the invention. Thermally induced radical polymerization is preferably used. Photochemically induced polymerization reactions are also conceivable.

[0053] A further independent aspect of the invention involves the plasma treatment of an ophthalmic lens. This advantageously reduces the surface stickiness of the lens without the need for a chemical coating (e.g., heparin in a dipping process). A preferred plasma treatment procedure and preferred plasma treatment parameters can be found in the above descriptions of the second aspect of the invention.

[0054] Further features of the invention emerge from the claims and the exemplary embodiments. The features and combinations of features mentioned above in the description, as well as the features and combinations of features mentioned below in the exemplary embodiments and / or shown alone, can be used not only in the respectively specified combination, but also in other combinations or on their own, without departing from the scope of the invention. Thus, embodiments are to be regarded as encompassed and disclosed by the invention which are not explicitly shown and explained in the exemplary embodiments, but which arise and can be produced through separate combinations of features from the explained embodiments. Embodiments and combinations of features are also to be regarded as disclosed which therefore do not have all the features of an originally formulated independent claim. Fig.1 a schematic plan view of an ophthalmic lens according to an embodiment of the invention;.

[0055] Preferred embodiment of the invention

[0056] Fig. 1 shows a schematic top view of an ophthalmic lens 10 according to an embodiment of the invention. The ophthalmic lens 10 is embodied as a soft intraocular lens (IOL) and has a base body 12. In the present example, the base body 12 has a first region 14a and a second region 14b, which differ with respect to at least one parameter from the group of stiffness and hardness. For this purpose, the regions 14a, 14b can, for example, be made from different embodiments of an ophthalmic composition discussed in more detail below or can be post-treated differently. In the simplest embodiment, however, the regions 14a, 14b are made from the same ophthalmic composition and do not differ at the molecular level.In the illustrated embodiment, the IOL 10 has an optical part 16 and a generally optional haptic part 18, which in this case is wing-shaped. However, the geometry of the haptic part 18 can vary fundamentally and, for example, be hook-shaped.

[0057] To produce the IOL 10, an ophthalmic composition according to the invention was used, comprising comonomer groups A) to C), at least one comonomer group which is D), E) or a mixture thereof, and at least one crosslinker F). A) denotes at least one (meth)acrylate having at least one aromatic group, B) at least one (meth)acrylate having an aliphatic or non-aromatic cyclic or non-aromatic heterocyclic group, C) at least one (meth)acrylate having at least one hydroxy group, D) at least one (meth)acrylamide having an aromatic group and having an aliphatic or non-aromatic cyclic or non-aromatic heterocyclic group, and E) a mixture of at least one (meth)acrylamide having two aromatic groups and at least one (meth)acrylamide having two aliphatic and / or non-aromatic cyclic and / or non-aromatic heterocyclic groups.

[0058] The comonomer groups A) to D) / E) are discussed in more detail in Table 2 below, along with their significance, exemplary compounds, and exemplary mass fractions of the total weight of the composition. The mass fractions refer to the sum of all compounds of the respective class A) to D) / E). Therefore, if, for example, class A) contains three different compounds and has a mass fraction of 50 wt.% of the total weight of the composition, this mass fraction is calculated from the sum of the respective mass fractions of the three compounds of class A).

[0059] Table 2: Comonomer groups A) to D) / E)

[0060] This means:

[0061] PEMA 2-phenylethyl methacrylate

[0062] PEA 2-phenyl ethyl acrylate

[0063] EGPEA ethylene glycol phenyl ether acrylate nßuA butyl acrylate iBuA isobutyl acrylate

[0064] EHA 2-Ethylhexylacrylate

[0065] HEMA 2-hydroxyethyl methacrylate

[0066] HEA 2-hydroxyethyl acrylate

[0067] HBA 4-hydroxybutyl acrylate

[0068] BIPA N-Benzyl-N-isopropylacrylamide

[0069] BBA N-Benzyl-N-butylacrylamide

[0070] BIBA N-Benzyl-N-isobutylacrylamide

[0071] BIPEA N-Benzyl-N-isopentylacrylamide

[0072] BMA N-Benzyl-N-methylacrylamide

[0073] BHEA N-Benzyl-N-2-hydroxyethylacrylamide As already mentioned, acrylates and corresponding methacrylates, as well as acrylamides and corresponding methacrylamides, can generally be exchanged for one another or mixed with one another. Alkyl group substituents can generally have between 1 and 12 carbon atoms within the scope of the present disclosure. For example, a compound of the general formula III can generally be used as (meth)acrylamide: be used, where the alkyl radical R 2may be unbranched or branched and unsubstituted or, in particular, substituted by one, two or more hydroxy groups. If the alkyl radical R 2 is substituted with one or more hydroxy groups, preferably at least one hydroxy group is terminal. The compound of formula III can preferably be N-benzyl-N-isopropylacrylamide (BIPA):

[0074] The compound of formula III can be N-benzyl-N-isobutylacrylamide (BIBA): (BIBA).

[0075] The compound of formula III can be N-benzyl-N-isopentylacrylamide (BIPEA):

[0076] The compound of formula III can be N-benzyl-N-2-hydroxyethylacrylamide (BHEA):

[0077] In this case, the ethyl radical R 2substituted with a terminal hydroxy group, so that the compound BHEA can interact with the comonomer C) as well as with water molecules. In general, several, for example two, hydroxy groups can be provided as substituents, so that the compound of group D) can correspond to the general formula IV, in which n and m are each selected between 1 and 10, so that the sum n+m is between 2 and 11.

[0078] As already mentioned, instead of the acrylamides shown, corresponding methacrylamides and any mixtures thereof can also be used.

[0079] The advantageous interactions of the various comonomer groups A) to D) (or E)) are explained in more detail in the following compositions V and VI using respective exemplary compounds.

[0080] Composition V uses, as examples, the compounds EGPEA (comonomer type A)), nBuA (comonomer type B)), 2-HEMA (comonomer type C)), and BBA (comonomer type D)). It can be seen that in composition V, due to the selected structural similarities of the individual comonomer types A) to D) (analogous to E)), advantageous intermolecular interactions develop, with the hybrid (meth)acrylamide D) acting as a kind of mediator between groups A) and B). The aryl group of (meth)acrylamide D) also advantageously leads to an increase in the refractive index and forms TT-TT interactions with the aryl groups of the aromatic monomer A), which leads to greater structural strength of the polymer. The alkyl group of (meth)acrylamide D) increases the flexibility of the material.In contrast, the comonomer type C) can form hydrogen bonds to water molecules enclosed in the polymer as well as to the amide group of the (meth)acrylamide D) / E) via its terminal and sterically unhindered hydroxy group.

[0081] The same considerations apply to compositions VI, in which the compounds PEA (comonomer type A)), iBuA (comonomer type B)), 2-HEMA (comonomer type C)) and BIPA (comonomer type D)) are used as examples:

[0082] (VI).

[0083] Following the material design strategy described above, several novel ophthalmic compositions were prepared, polymerized, and analyzed as examples. The resulting polymeric biomaterials demonstrated promising properties in terms of material flexibility and tensile strength, as well as high refractive indices. In addition to the introduced monomers (2-(5-chloro-2H-benzotriazol-2-yl)-6-(1,1-dimethylethyl)-4-ethenylphenol) (IIVAM) as a UV blocker for ophthalmic materials, 2,2'-azobis(2-methylpropionitrile) (AIBN) is used for thermal radical initiation of the composition. An exemplary ophthalmic composition, designated "T-30C," which exists as an optically clear biomaterial in the polymerized state, is listed in Table 3 with the respective substance groups and quantities used.

[0084] Table 3: Inventive ophthalmic composition T-30C However, the ophthalmic composition is not only suitable for the production of clear ophthalmic biomaterial. By adding an appropriate amount (usually < 1.0 wt%) of yellow dye (Group H)), the ophthalmic composition can be easily adapted to produce a yellow biomaterial. The amount of yellow dye used in the composition can be selected within a wide concentration range as required. In this exemplary case, it was adjusted so that the composition had the same optical properties in terms of percentage transmission per wavelength in the range of 400 nm to 500 nm as the commercially available yellow biomaterial ZEISS CT Lucia (Acrylmex Y). This was achieved by adding a small amount (< 1.0 wt%) of the yellow dye 4-(3-vinylphenylazo)diphenylamine (3VPADPA or VPAD), which absorbs blue light, to the composition “T-30C” shown above.The correspondingly adapted composition is hereinafter referred to as “T-30Y”.

[0085] Average physical property values ​​were determined based on measurements of three clear (T-30C) and three yellow (T-30Y) biomaterial batches. An overview of the average biomaterial properties is provided in Table 4 for the preferred clear version of the ophthalmic composition, T-30C, and in Table 5 for the preferred yellow version of the ophthalmic composition, T-30Y.

[0086] Table 4: Properties of the optically clear material T-30C Table 5: Properties of the yellow material T-30Y

[0087]

[0088] In addition to the properties highlighted in Table 4 and Table 5, the biomaterial also exhibits excellent resistance to glistening. The type and amount of crosslinker used for an elastomer influences the mechanical properties and can also be used to reduce glistening. However, even with compositions known from the state of the art, changing the amount of crosslinker alone is not sufficient to meet all of the material's stated requirements, including reducing glistening. However, it has been found that even with a constant amount of crosslinker (e.g., approximately 3 wt%), the addition of (meth)acrylamide comonomers D) / E) contributes to steer the material properties in the desired direction.

[0089] In contrast to prior art, low-glistening, hydrophilic compositions that require storage in saline solution, the ophthalmic composition according to the invention offers both the possibility of dry storage and the possibility of steam sterilization. The water absorption capacity of the polymerized biomaterial is tailored so that these opposing requirements can be met with a single material.

[0090] For experimental confirmation, a glistening study was conducted. During accelerated aging, five IOLs, each with a refractive power of 20.0 D, were prepared from an ophthalmic composition according to the invention and stored in 0.9% sodium chloride solution at 45°C for 24 hours. The lenses were then incubated at 37°C for 2.5 hours and examined under a microscope using a digital camera and vacuole detection software (Image J). It was found that two of the five IOLs remained completely free of microvacuoles (MV) during the accelerated aging process. The other three IOLs exhibited a very low microvacuole count of approximately 0.61 MV / mm. 2This density not only corresponds to grade 0 on the Miyata scale, but is also well below the MV density achieved by the vast majority of currently commercially available IOL models in previous studies. The results of these previous studies are summarized in Table 6.

[0091] Table 6: Summary of the results of glistening studies of different IOL models

[0092] Based on the test results, the material composition T-30C can be described not only as glistening-free, but also as suitable for the production of microvacuole-free lenses. It is important to note that the preferred ophthalmic composition described in Table 3 can be adapted both with regard to the compounds used for the individual comonomer groups and with regard to the concentration ranges of the individual comonomer groups. Thus, numerous alternative formulations of the composition are possible within the scope of the present disclosure, which also have the advantageous

[0093] properties of the material according to the invention.

[0094] It was found that a biomaterial made from the composition of the invention with a water absorption capacity of -1.8 wt.% results in sufficient water distribution within the polymer to prevent glistening. At the same time, the water content is low enough to prevent lens swelling after implantation, thus eliminating the need for storage in an aqueous environment. Furthermore, the water content and chemical composition allow the lenses to be steam sterilized.

[0095] It was found that lenses with a 5 mm optical zone, made from a material according to the invention, for example, T-30C or T-30Y, can be injected without great effort using a Medicel Accuject injector with a 1.8 mm cartridge. This meets the requirements for microincision cataract surgery. IOLs according to the invention could also be injected without difficulty using an Accuject 2.2 cartridge. The injection tests were conducted in vitro using an OVD (ophthalmic viscoelastic device) or a saline solution (BSS). This suitability results from both the high refractive index of the material according to the invention, which requires a lower lens thickness, and its flexibility, which is strongly influenced by the low glass transition temperature (Tg) of the material.The latter should be designed very carefully, as too high a Tg can stiffen the polymer, and too low a Tg can complicate the processing process. The inventive composition T-30C / T-30Y has a Tg of approximately 6 °C, which is at the lower end of the range for hydrophobic acrylate-based IOL materials (see Table 1). In addition to lens production, mechanical tests were also conducted to demonstrate the processability of the biomaterial produced from the inventive composition.

[0096] Furthermore, a T-30C biomaterial was characterized using dynamic mechanical thermal analysis (DMTA). To simulate the conditions during cryo-turning and cryo-milling of the materials, the respective average rotational speeds (7,500 rpm = 125 Hz) and milling (14,000 rpm = 233 Hz) were used as loading frequencies. After the experimental analysis, the shear storage modulus G' and the shear loss modulus G" were determined. Several different non-covalent bonds can form between the functional polymer groups of the composition according to the invention (cf. Compositions V and VI). These forces can be overcome when the biomaterial is heated (e.g., during steam sterilization) and automatically reform when the material is cooled.The DMTA tests showed that the Tg only changes by approximately 2 K when the loading frequency is doubled, enabling good stability throughout the machining process. Furthermore, the biomaterial of the invention exhibits a significantly lower decrease in material stiffness with increasing temperature in the glassy state (shear storage modulus G'). Therefore, when the biomaterial of the invention is machined (e.g., at -20 °C), it exhibits higher stiffness. At room temperature and above, T-30C / Y is significantly softer, which, as already mentioned, leads to better implantability.

[0097] In addition to the advantages already highlighted, the biomaterial according to the invention was also tested against standard requirements for ophthalmic lenses. These tests include photostability studies, including the UV stability of the biomaterial, and the extraction of the storage solution. These tests were also successfully passed. Furthermore, a series of biocompatibility tests were conducted, including a cytotoxicity study and a risk analysis, which were also successfully completed. Tests on the adhesiveness of the material were also conducted, which are particularly important because the biomaterial according to the invention has a low Tg and high flexibility. For this purpose, biomaterial discs according to the invention with a smooth surface were cut and pushed together with a defined force before the force required for detachment was measured.In combination with additional injection tests, it was determined that no chemical coating (e.g., heparin dip coating) is required for this biomaterial, and a simple, purpose-developed plasma treatment is sufficient to reduce surface stickiness. This plasma treatment process also proved to be stable over a long period of more than a year, ensuring safe lens deployment after the storage period. The plasma treatment was performed in a furnace with an RF plasma generator (13.56 MHz) and in a mixed atmosphere of oxygen and argon (23 sccm O2, 127 sccm Ar, 400 mtorr) at 400 W and for 5 minutes per IOL side. In the plasma furnace, the oxygen is converted to ozone, which intensifies the treatment.

[0098] Finally, the biomaterial according to the invention was tested for its suitability for steam sterilization. For the tests, 1.0 mm thick discs with a diameter of 6.0 mm were produced by cryo-rotation from the biomaterial and from several hydrophobic acrylate materials known from the state of the art. The discs were hydrated in autoclavable vessels in an appropriate amount of aqueous solution for 48 hours at room temperature. All vessels were transferred to an autoclave and heated to 121 °C at the standard rate (+6.6 K / min, 15 min total). The vessels were held at this temperature for 30 min before being slowly cooled to room temperature (21 °C). Cooling should preferably be carried out at the slowest possible rate (e.g., -0.07 K / min, 24 h total). The discs were then inspected for visible defects, particularly microvacuoles that had formed inside the material.In the test conducted, the lenses with the T-30C composition showed no permanent damage due to microvacuoles and outperformed the hydrophobic reference samples in this regard. Thus, the biomaterials and lenses according to the invention are suitable for steam sterilization.

[0099] Further exemplary embodiments of the ophthalmic composition according to the invention are given in Table 7 below. The biomaterials and lenses produced therefrom have the same advantageous properties as the previously discussed material T-30C / Y. The alternative compositions given in Table 7 follow the described strategy and show, by way of example and not exhaustively, which variations are possible either through a comonomer exchange and / or through a change in the group proportions used in order to obtain comparable optical, physical, and mechanical properties of the corresponding biomaterials. Table 7: Exemplary embodiments of the ophthalmic composition according to the invention

[0100] composition

[0101] The parameter values ​​specified in the documents for defining process and measurement conditions for characterizing specific properties of the subject matter of the invention are to be considered as encompassed by the scope of the invention, even in the case of deviations—for example, due to measurement errors, system errors, weighing errors, DIN tolerances, and the like.

[0102] 10 lens (IOL)

[0103] 12 Base body 14a first area

[0104] 14b second area

[0105] 16 optical part

[0106] 18 haptic part

Claims

Patent claims Ophthalmic composition for producing an ophthalmic lens (10), comprising comonomer groups A) to C), at least one comonomer group which is D), E) or a mixture thereof, and at least one crosslinker F), wherein A) at least one (meth)acrylate having at least one aromatic group; B) at least one (meth)acrylate having an aliphatic or non-aromatic cyclic or non-aromatic heterocyclic group; C) at least one (meth)acrylate having at least one hydroxy group; D) at least one (meth)acrylamide having an aromatic group and having an aliphatic or non-aromatic cyclic or non-aromatic heterocyclic group; and E) a mixture of at least one (meth)acrylamide having two aromatic groups and at least one (meth)acrylamide having two aliphatic and / or non-aromatic cyclic and / or non-aromatic heterocyclic groups; characterized in that, based on the total weight of the ophthalmic composition, a proportion of the comonomer group A) is between 30 wt.% and 60 wt.%; of the comonomer group B) is between 10 wt.% and 45 wt.%; of the comonomer group C) is between 5 wt.% and 30 wt.%; of the sum of the comonomer groups D) and E) is between 1 wt.% and 14 wt.%; and of the crosslinker F) is at most 5 wt.%, in particular between 0.5 wt.% and 5 wt.%. Ophthalmic composition according to claim 1, characterized in that A) comprises or is 2-phenylethyl (meth)acrylate, ethylene glycol phenyl ether (meth)acrylate or a mixture thereof; and / or B) comprises or is butyl(meth)acrylate, isobutyl(meth)acrylate, 2-ethylhexyl(meth)acrylate or a mixture thereof; and / or C) comprises or is 2-hydroxyethyl (meth)acrylate, 4-hydroxybutyl (meth)acrylate or a mixture thereof; and / or D) includes or is N-benzyl-N-isopropyl(meth)acrylamide, N-benzyl-N-butyl(meth)acrylamide, N-benzyl-N-isobutyl(meth)acrylamide, N-benzyl-N-isopentyl(meth)acrylamide, N-benzyl-N-pentyl(meth)acrylamide, N-benzyl-N-methyl(meth)acrylamide or a mixture thereof; and / or E) N,N-Dibenzyl(meth)acrylamide and N,N-Diisopropyl(meth)acrylamide, N,N- Dibenzyl(meth)acrylamide and N,N-dibutyl(meth)acrylamide, N,N- Dibenzyl(meth)acrylamide and N,N-isobutyl(meth)acrylamide, N,N- Dibenzyl(meth)acrylamide, N,N-diisopentyl(meth)acrylamide and N,N-dipentyl(meth)acrylamide, N,N-dibenzyl(meth)acrylamide and N,N- Dimethyl(meth)acrylamide or a mixture thereof; and / or F) comprises a crosslinker having at least two (meth)acrylate groups, wherein the crosslinker comprises or is in particular 1,4-butanediol diacrylate and / or ethylene glycol dimethacrylate. Ophthalmic composition according to claim 1 or 2, characterized in that it contains at least one further component G), H), I) or a mixture thereof, wherein G) at least one preferably covalently bondable UV absorber; H) at least one preferably covalently bondable dye for modifying the light absorption properties; and I) denotes a polymerization initiator. Ophthalmic composition according to claim 3, characterized in that based on the total weight of the ophthalmic composition, a proportion of the component G) maximum 2% by weight; and / or H) maximum 5% by weight; and / or I) a maximum of 3 wt.%; ophthalmic composition according to claim 3 or 4, characterized in that the UV absorber G) comprises or is 2-(5-chloro-2H-benzotriazol-2-yl)-6-(1,1-dimethylethyl)-4-ethenylphenol) and / or that the dye H) comprises or is 4-(3-vinylphenylazo)diphenylamine. Ophthalmic lens (10), in particular a soft intraocular lens, which is at least partially made from an ophthalmic composition according to any one of claims 1 to 5.Ophthalmic lens (10) according to claim 6, characterized in that it has a refractive index nD,20°C > 1.51 in a non-hydrated state; and / or a refractive index nO,35°C > 1.50 in a hydrated state; and / or a Shore A hardness of less than 80 (t=3 s) and / or a Shore A hardness of less than 50 (t=10 min); and / or a glass transition temperature between 0°C and 15°C, in particular between 4°C and 9°C; and / or a water absorption capacity at 35°C between 0.5 wt.% and 3.5 wt.%, in particular between 1.5 wt.% and 2.5 wt.%; and / or an Abbe number of at least 30, preferably at least 40. Ophthalmic lens (10) according to one of claims 6 or 7, characterized in that. in an in vitro glistening test by accelerated ageing, in which the lens (10) is first placed in a saline solution at 45 °C ± 1 °C for 24 h and then at 37 °C ± 1 °C for 2.5 h, a microvacuole density of not more than 10 MVs / mm 2 , preferably not more than 1 MVs / mm 2 Ophthalmic lens (10) according to one of claims 6 to 8, characterized in that it is steam-sterilized and / or plasma-treated and / or stored in a preferably non-hydrated state in a storage cartridge and / or in an implantation tool for implanting the lens (10) into an eye.

Images